Howard Scher
MD
D. Wayne Calloway Chair in Urologic Oncology
👥Biography 个人简介
Howard Scher at Memorial Sloan Kettering co-led the AFFIRM trial establishing enzalutamide in post-docetaxel mCRPC and has made fundamental contributions to understanding androgen receptor biology, AR-V7 splice variant as a resistance biomarker, and circulating tumor cell analysis for response monitoring in prostate cancer. His work connecting AR biology to therapeutic resistance drives ongoing treatment innovation.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Howard Scher 的研究动态
Follow Howard Scher's research updates
留下邮箱，当我们发布与 Howard Scher（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment